Literature DB >> 16849717

Increased recovery of Moraxella catarrhalis and Haemophilus influenzae in association with group A beta-haemolytic streptococci in healthy children and those with pharyngo-tonsillitis.

Itzhak Brook1, Alan E Gober1.   

Abstract

The inflamed tonsils harbour numerous types of bacteria, alone or in combination with group A beta-haemolytic streptococci (GABHS). The cohabitation of the tonsils by GABHS and certain other bacterial species may contribute to the inflammatory process and the failure of penicillin therapy. This study evaluated the recovery of Moraxella catarrhalis, Haemophilus influenzae, Staphylococcus aureus and Streptococcus pneumoniae in association with GABHS in healthy children and those with acute pharyngo-tonsillitis (APT). Pharyngo-tonsillar cultures were obtained from 548 children with APT and 866 healthy children. GABHS was recovered from 112 (20.4%) children with APT. Of the 114 H. influenzae isolates, 32 were recovered in association with GABHS (29% of all patients who had GABHS) and 82 were isolated without GABHS (19%) (P=0.0267). Of the 69 M. catarrhalis isolates, 25 were recovered in association with GABHS (22% of all patients who had GABHS) and 44 were isolated without GABHS (10%) (P=0.0012). In contrast, there was no association between the isolation of GABHS and the recovery of Staph. aureus or Strep. pneumoniae. GABHS was recovered from 104 (12%) healthy children. Of the 69 M. catarrhalis isolates, 24 were recovered in association with GABHS (23% of all patients who had GABHS) and 80 were isolated without GABHS (10%) (P=0.006). There was no association between the isolation of GABHS and the recovery of H. influenzae, Staph. aureus or Strep. pneumoniae. This study demonstrates an association between the recovery of GABHS and H. influenzae and M. catarrhalis from pharyngo-tonsillar cultures of patients with APT and M. catarrhalis from pharyngo-tonsillar cultures of healthy children.

Entities:  

Mesh:

Year:  2006        PMID: 16849717     DOI: 10.1099/jmm.0.46325-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  7 in total

1.  Penicillin failure in the treatment of streptococcal pharyngo-tonsillitis.

Authors:  Itzhak Brook
Journal:  Curr Infect Dis Rep       Date:  2013-06       Impact factor: 3.725

2.  Protective mechanisms of respiratory tract Streptococci against Streptococcus pyogenes biofilm formation and epithelial cell infection.

Authors:  Tomas Fiedler; Catur Riani; Dirk Koczan; Kerstin Standar; Bernd Kreikemeyer; Andreas Podbielski
Journal:  Appl Environ Microbiol       Date:  2012-12-14       Impact factor: 4.792

Review 3.  The role of the local microbial ecosystem in respiratory health and disease.

Authors:  Wouter A A de Steenhuijsen Piters; Elisabeth A M Sanders; Debby Bogaert
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-08-19       Impact factor: 6.237

Review 4.  Treatment Challenges of Group A Beta-hemolytic Streptococcal Pharyngo-Tonsillitis.

Authors:  Itzhak Brook
Journal:  Int Arch Otorhinolaryngol       Date:  2016-06-03

5.  Lactoferrin versus Long-Acting Penicillin in Reducing Elevated Anti-Streptolysin O Titer in Cases of Tonsillopharyngitis.

Authors:  Aida Ahmed Abdelmaksoud; Asmaa Nafady; Shamardan Ezzeldin Sayed Bazeed; Mahmoud Khalefa; Mahmoud K Elsamman; Mennatallah Ali Abdelrhman Sayed; Heba Mohammad Qubaisy; Ali A Ghweil; Zaki F Aref
Journal:  Infect Drug Resist       Date:  2022-09-06       Impact factor: 4.177

Review 6.  Viral and bacterial interactions in the upper respiratory tract.

Authors:  Astrid A T M Bosch; Giske Biesbroek; Krzysztof Trzcinski; Elisabeth A M Sanders; Debby Bogaert
Journal:  PLoS Pathog       Date:  2013-01-10       Impact factor: 6.823

7.  Beta-lactam effects on mixed cultures of common respiratory isolates as an approach to treatment effects on nasopharyngeal bacterial population dynamics.

Authors:  David Sevillano; Lorenzo Aguilar; Luis Alou; María-José Giménez; Natalia González; Martha Torrico; Fabio Cafini; Pilar Coronel; José Prieto
Journal:  PLoS One       Date:  2008-12-04       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.